The Hypothesis: Mechanotransduction as the Primary Driver of Senescence

Recent findings show that the age-related shift toward sVEGFR1 production and the resulting VEGFR1-YAP1 axis drive capillary rarefaction Science, Frontiers. I believe this isn't just a ligand-sequestration problem; it’s a failure of Endothelial Mechanotransduction Calibration.

My hypothesis is that VEGFR1-YAP1 signaling is a compensatory, if maladaptive, reaction to the loss of laminar shear stress sensing. In young, healthy endothelium, VEGFR2/β3-integrin crosstalk PubMed functions as a tension gauge, turning fluid shear stress into a proliferative signal. In aged tissue, the shift to sVEGFR1 sequestration destabilizes this complex. The cell then misreads this lack of canonical angiogenic input as flow-stasis or vessel instability. The upregulation of the VEGFR1-YAP1 axis is a desperate, misdirected attempt by the cell to stabilize the vessel structurally via senescence (stiffening the cytoskeleton) instead of functionally through angiogenesis.

The Mechanistic Loop

1. Signal Decoupling: Age-related alternative splicing of VEGFR1 depletes the pool of membrane-bound VEGFR2/β3-integrin complexes. The cell effectively loses its ability to interpret hemodynamic shear as a growth signal.
2. Transcriptional Misinterpretation: When the cell fails to "see" flow, it interprets the absence of VEGFR2 signaling as evidence that the vessel is failing. It activates the VEGFR1-YAP1 axis, not to promote growth, but to lock itself into a pro-inflammatory, senescent state intended to prevent leakage.
3. The Vicious Cycle: Senescent cells release SASP factors that further shift splicing, trapping the endothelial cell in a constitutive sVEGFR1-production loop.

Proposed Test

To falsify this, we need to see if restoring VEGFR2/β3-integrin signaling—without just dumping in more VEGF—can override the VEGFR1-YAP1 senescence program.

• Experimental Design: Use optogenetic recruitment of β3-integrin to the plasma membrane in aged mice, independent of ligand binding.
• Prediction: If senescence is just a byproduct of mechanotransduction failure, forced clustering of integrins should suppress the VEGFR1-YAP1 pathway and rescue angiogenic competence, even in the presence of existing sVEGFR1.

Therapeutic Implications

Targeting the splicing machinery directly Science is risky given the systemic nature of VEGFR1 expression. If this hypothesis is correct, however, we could treat capillary rarefaction by pharmacologically boosting endothelial sensitivity to shear—using integrin-activation small molecules, for example. This would lower the threshold needed to bypass the YAP1 senescence trap, avoiding the tumorigenic risks of global VEGF supplementation while restoring the vessel's innate ability to respond to physiological perfusion.